{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:24:57Z","timestamp":1772166297830,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"scientific research project of health commission of weifang","award":["wfwsjs-2018-096"],"award-info":[{"award-number":["wfwsjs-2018-096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4\u2009\u00d7\u20093.2\u00a0cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13019-021-01741-2","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T10:02:33Z","timestamp":1642327353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-3380","authenticated-orcid":false,"given":"Chunbo","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianpeng","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,16]]},"reference":[{"issue":"4","key":"1741_CR1","first-page":"681","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu H, Guo L, Zhang J, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019;11(4):681\u201390.","journal-title":"MAbs"},{"issue":"10","key":"1741_CR2","doi-asserted-by":"publisher","first-page":"e2013770","DOI":"10.1001\/jamanetworkopen.2020.13770","volume":"3","author":"Z Wang","year":"2020","unstructured":"Wang Z, Ying J, Xu J, et al. Safety, Antitumor activity, and pharmacokinetics of toripalimab, a programmed cell death 1 inhibitor, in patients with advanced non-small cell lung cancer: a phase 1 trial. JAMA Netw Open. 2020;3(10):e2013770.","journal-title":"JAMA Netw Open"},{"issue":"9804","key":"1741_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","volume":"378","author":"P Goldstraw","year":"2011","unstructured":"Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727\u201340.","journal-title":"Lancet"},{"issue":"1","key":"1741_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1200\/JCO.2009.23.2272","volume":"28","author":"R Arriagada","year":"2010","unstructured":"Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35\u201342.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1741_CR5","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. NEJM. 2018;378(21):1976\u201386.","journal-title":"NEJM"},{"issue":"6","key":"1741_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):786\u201395.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1741_CR7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","volume":"26","author":"M Lu","year":"2020","unstructured":"Lu M, Zhang P, Zhang Y, et al. Efficacy, safety, and biomarkers of Toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. Clin Cancer Res. 2020;26(10):2337\u201345.","journal-title":"Clin Cancer Res"},{"key":"1741_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","volume":"130","author":"J Yang","year":"2020","unstructured":"Yang J, Dong L, Yang S, et al. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer. 2020;130:182\u201392.","journal-title":"Eur J Cancer"},{"issue":"32","key":"1741_CR9","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","volume":"37","author":"X Sheng","year":"2019","unstructured":"Sheng X, Yan X, Chi Z, et al. Axitinib in combination with Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J Clin Oncol. 2019;37(32):2987\u201399.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1741_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/cac2.12019","volume":"40","author":"H Qiu","year":"2020","unstructured":"Qiu H. Safety and efficacy of toripalimab in advanced gastric cancer: a new clinical trial bringing hope for immunotherapy in gastric cancer. Cancer Commun. 2020;40(4):194\u20136.","journal-title":"Cancer Commun"},{"issue":"1","key":"1741_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12885-019-5624-2","volume":"19","author":"F Eichhorn","year":"2019","unstructured":"Eichhorn F, Klotz LV, Bischoff H, et al. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II\/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. BMC Cancer. 2019;19(1):413.","journal-title":"BMC Cancer"},{"issue":"1","key":"1741_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","volume":"158","author":"MJ Bott","year":"2019","unstructured":"Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):269\u201376.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"1741_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","volume":"106","author":"MJ Bott","year":"2018","unstructured":"Bott MJ, Cools-Lartigue J, Tan KS, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106(1):178\u201383.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"1741_CR14","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.athoracsur.2017.03.038","volume":"104","author":"JE Chaft","year":"2017","unstructured":"Chaft JE, Hellmann MD, Velez MJ, Travis WD, Rusch VW. Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors. Ann Thorac Surg. 2017;104(3):e217\u20138.","journal-title":"Ann Thorac Surg"},{"issue":"23","key":"1741_CR15","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-021-01741-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-021-01741-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-021-01741-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T22:51:28Z","timestamp":1674427888000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-021-01741-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1741"],"URL":"https:\/\/doi.org\/10.1186\/s13019-021-01741-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-151057\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-151057\/v1","asserted-by":"object"}]},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval at The First Affiliated Hospital, Weifang Medical University (Weifang People\u2019s Hospital). The patient in this study signed an informed written consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}